In a clinical trial that included SGLT2 inhibitors together with basal insulin and metformin as an intensive intervention, the group receiving SGLT2 inhibitors saw higher rates of remission than the traditional group (24.7% vs. 16.9%), and their risk of diabetes recurrence was cut by 43% [47]. The gene discussed is INS; the disease is diabetes mellitus.